Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05502289
Other study ID # CR-6493
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 19, 2022
Est. completion date October 17, 2022

Study information

Verified date November 2023
Source Johnson & Johnson Vision Care, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a bilateral-wear, dispensing, randomized, controlled, double-masked, 2-sequence × 2-period crossover study to evaluate ocular physiology following contact lens wear.


Recruitment information / eligibility

Status Completed
Enrollment 66
Est. completion date October 17, 2022
Est. primary completion date October 17, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 39 Years
Eligibility Inclusion Criteria: Potential subjects must satisfy all the following criteria to be enrolled in the study. The subject must: 1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. Be between 18 and 39 (inclusive) years of age at the time of screening. 4. By self-report, habitually wear soft contact lenses in both eyes in a daily reusable or daily disposable wear modality (i.e., not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 2 days per week during the past month. 5. Possess a wearable pair of spectacles that provide correction for distance vision. 6. Have the spherical component of their vertex-corrected distance refraction must be between -0.875 to -4.625 DS (inclusive) in each eye. 7. Have the magnitude of the cylindrical component of their vertex-corrected distance refraction between 0.625 DC and 1.625 DC in both eyes. 8. Have the cylinder axis of their distance refraction between 165° and 15° (i.e., 180±15°, inclusive) or between 75° and 105° (i.e., 90±15°, inclusive) in each eye. 9. Have best corrected monocular distance visual acuity of 20/30 or better in each eye. Exclusion Criteria: Potential subjects who meet any of the following criteria will be excluded from participating in the study. The subject must not: 1. Be currently pregnant or lactating. 2. Be diabetic. 3. Be currently using any ocular medications or have any ocular infection of any type. 4. By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g., rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications. 5. Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g., SynergEyes, SoftPerm) within the past 6 months. 6. Be currently wearing monovision or multifocal contact lenses. 7. Be currently wearing lenses in an extended wear modality. 8. Have a history of strabismus or amblyopia. 9. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site. 10. Have participated in a contact lens or lens care product clinical trial within 7 days prior to study enrollment. 11. Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis). 12. Have fluctuations in vision due to clinically significant dry eye or other ocular conditions. 13. Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
TEST LENS
DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
CONTROL LENS
PRECISION1™ for Astigmatism Contact Lenses (P1fA)

Locations

Country Name City State
United States Sabal Eye Care Longwood Florida
United States Maitland Vision Center - North Orlando Ave Maitland Florida
United States Optometry Group, LLC Memphis Tennessee
United States Botetourt Eyecare, LLC Salem Virginia
United States Sacco Eye Group Vestal New York
United States Professional Vision Care Inc. - Westerville Westerville Ohio

Sponsors (1)

Lead Sponsor Collaborator
Johnson & Johnson Vision Care, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Eyes With Grade 3 or Higher Slit Lamp Findings Slit Lamp Findings (SLF) were assessed using a biomicroscope and was graded using the FDA grading scale (Grade: 0, 1,2, 3 and 4) with grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e. Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe). This was performed on each subject eye at every study visit (baseline, unscheduled visits and 1-week follow-up), however data collected at the 1-week follow-up is the primary endpoint. The data was then dichotomized into two groups. Those with grade 3 or higher and those with grade 2 or lower. The percentage of eyes with SLF with grade 3 or higher was reported for each lens type. 1-Week Follow-up
See also
  Status Clinical Trial Phase
Completed NCT00431392 - Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions Phase 2
Completed NCT06161012 - Evaluation of Delefilcon A and Senofilcon A Daily Disposable Toric Soft Contact Lenses Over Two Weeks of Wear N/A
Terminated NCT00708357 - Does eNOS Gene Polymorphism Play a Role in the Maintenance of Basal Vascular Tone in the Choroid or Optic Nerve Head? Phase 0
Completed NCT05291936 - Clinical Evaluation of Two Daily Disposable Toric Soft Contact Lenses Over One Week of Wear N/A
Withdrawn NCT00712777 - Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism N/A
Completed NCT00709423 - Effects of Moxaverine and Placebo on Ocular Blood Flow Phase 2
Completed NCT00708929 - Does Complement Factor H Gene Polymorphism Play a Role in the Regulation of Vascular Tone in the Choroid? N/A
Completed NCT00712400 - Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects N/A
Completed NCT01663688 - Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye N/A
Completed NCT05427539 - Feasibility Evaluation of Daily Disposable Toric Soft Contact Lenses Manufactured With an Alternative Hydration Process N/A
Completed NCT05713552 - Evaluation of ACUVUE® OASYS 1-Day for Astigmatism Contact Lenses With Alternative Lidstock N/A
Withdrawn NCT00406731 - Role of Endothelin- and Nitric Oxide-system in the Regulation of Optic Nerve Head Blood Flow During Changes in Ocular Perfusion Pressure Phase 2
Completed NCT00706927 - Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension N/A
Completed NCT00275730 - Effects of Indomethacin on Retinal and Choroidal Blood Flow in Healthy Volunteers N/A
Completed NCT00712764 - Role of Adenosine in the Control of Choroidal Blood Flow During Changes in Ocular Perfusion Pressure. N/A
Withdrawn NCT05530889 - Evaluating Quality of Life Benefits of ACUVUE® Theravision® With Ketotifen in Subjects With Ocular Allergies N/A
Completed NCT00312416 - Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise Phase 4
Completed NCT00712907 - Effects of Vitamin C on Hyperoxia-Induced Reduction of Retinal Blood Flow N/A
Completed NCT00431730 - Is There a Difference in Flicker Induced Vasodilatation Between Smokers and Non-Smokers? N/A
Withdrawn NCT00991900 - Short Term and Day to Day Reproducibility of Reflectometric Measurement of Retinal Oxygen Saturation in Healthy Subjects